Middleton Co Incma buys $9,923,879 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Middleton Co Incma scooped up 5,465 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 185,147 shares of Merck & Co. which is valued at $9,923,879.Merck & Co. makes up approximately 2.30% of Middleton Co Incma’s portfolio.

Other Hedge Funds, Including , Duff Phelps Investment Management Co reduced its stake in MRK by selling 9,330 shares or 20.1% in the most recent quarter. The Hedge Fund company now holds 37,093 shares of MRK which is valued at $1,988,185. Merck & Co. makes up approx 0.03% of Duff Phelps Investment Management Co’s portfolio. Moisand Fitzgerald Tamayo sold out all of its stake in MRK during the most recent quarter. The investment firm sold 200 shares of MRK which is valued $10,968. Telemus Capital added MRK to its portfolio by purchasing 33,418 company shares during the most recent quarter which is valued at $1,832,643. Merck & Co. makes up approx 0.30% of Telemus Capital’s portfolio.Granite Investment Partners reduced its stake in MRK by selling 14,020 shares or 46.86% in the most recent quarter. The Hedge Fund company now holds 15,898 shares of MRK which is valued at $871,846. Merck & Co. makes up approx 0.08% of Granite Investment Partners’s portfolio.

Merck & Co. opened for trading at $54.47 and hit $54.73 on the upside on Tuesday, eventually ending the session at $54.68, with a gain of 1.07% or 0.58 points. The heightened volatility saw the trading volume jump to 64,86,243 shares. Company has a market cap of $151,356 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.